Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
3 Weight-Loss Drug Stocks To Consider For 2026
01:58pm, Friday, 21'st Nov 2025
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl
Novo Nordisk: The Sell-Off Is Getting Absolutely Ridiculous
12:05pm, Friday, 21'st Nov 2025
Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering N
Big News for Novo Nordisk Stock Investors
10:10am, Friday, 21'st Nov 2025
Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 21'st Nov 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
09:00am, Friday, 21'st Nov 2025
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)
08:25am, Friday, 21'st Nov 2025
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much t
Denmark compensates patients for vision loss linked to Novo Nordisk drugs
08:00am, Friday, 21'st Nov 2025
Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient Compensat
What's Going On With Novo Nordisk Stock?
05:45am, Friday, 21'st Nov 2025
Novo Nordisk (NVO 2.86%) is losing market share in the lucrative weight loss treatment category.
Novo Nordisk: One Of The Most Mispriced Alphas In The Market
05:25pm, Thursday, 20'th Nov 2025
Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market leadership. NVO dominates international markets with 72% share and 335% Wegovy s
Novo Nordisk: Will Wegovy And Pipeline Spark Rally?
12:51pm, Thursday, 20'th Nov 2025
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 bi
Novo Nordisk: Potential Winner With Value Trap Risks
10:09am, Thursday, 20'th Nov 2025
NVO's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock prices/performance, upon the materialization of positive catalyst/bullish support. This is signific
Obesity-drugmaker Novo Nordisk helps drive Denmark's fastest growth in years
08:24am, Thursday, 20'th Nov 2025
Denmark's seasonally adjusted gross domestic product grew by 2.3% in the third quarter, a preliminary reading from Statistics Denmark showed early Thursday. The main driver of growth was the pharmaceu
Novo Nordisk Just Saved Denmark's Economy--But for How Long?
06:45am, Thursday, 20'th Nov 2025
Danish GDP didn't just rebound in the third quarterâit snapped back with a force the country hasn't seen since late 2021, and the catalyst was unmistakable. A
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
06:04am, Thursday, 20'th Nov 2025
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progre
